China Study Finds Cilostazol Better Than Aspirin After Stroke
This article was originally published in PharmAsia News
Chinese researchers have determined cilostazol, an anti-clotting drug, may be safer than aspirin for some people who have had a stroke. Such patients are considered at higher risk of a cerebral hemorrhage, but the anti-platelet drug appears to have a long-term effect in low doses. The researchers' work was published online by the journal The Lancet Neurology. Cilostazol is made in China by Otsuka Pharmaceutical under the brand Pletal. (Click here for more
You may also be interested in...
Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.